Research and Markets: Heart Failure - Pumping Up Therapy Will Prevent Failure
Dublin, (PRWEB) June 14, 2005
Research and Markets (http://www. researchandmarkets. com/reports/c18933 (http://www. researchandmarkets. com/reports/c18933)) has announced the addition of Stakeholder Insight: Heart Failure - Pumping Up Therapy Will Prevent Failure to their offering
During the past two decades, heart failure has emerged as a major chronic disease among the elderly population in the major pharmaceutical markets. The leading cause of hospitalization among patients over the age of 65 in Western markets, heart failure represents a major burden for healthcare systems but is a highly attractive development market for pharmaceutical and medical device companies.
183 physician interviews were carried out across the seven major pharmaceutical markets, including cardiologists and primary care physicians. Key opinion leader interviews were carried out with heart failure specialists. The report includes estimated prevalence and incidence of heart failure by country for the seven major pharmaceutical markets. Detailed treatment trees show chronic and acute heart failure patient flows at country levels.
The diagnosis and treatment of chronic heart failure is sub-optimal with physicians failing to follow established guidelines. This suggests the need for continued physician education and a greater communication between the various physician types who manage heart failure patients. Prevention along with improved treatment may be needed to stem the growth of heart failure and limit the societal burden of the disease.
This research reveals that acute heart failure patients experience a high rate of re-hospitalization, suggesting that there is a strong unmet need for more effective treatment in acute heart failure in order to improve outcomes. New therapeutic options may provide a solution to this issue.
This report identifies the future direction of therapy, the remaining unmet needs, and the opportunities for both pharmaceutical and medical device companies. It can help the reader determine when and how therapies are prescribed, which compounds within each class lead prescriptions, and understand physician prescribing practices. The report examines best patient treatment protocols and improvements that need to be made to produce better patient outcomes.
For more information visit http://www. researchandmarkets. com/reports/c18933 (http://www. researchandmarkets. com/reports/c18933)
Laura Wood
Senior Manager
Research and Markets
Press@researchandmarkets. com
Fax: +353 1 4100 980
# # #
